AI Article Synopsis
- Obstructive sleep apnoea (OSA) is prevalent among elderly patients with cardiovascular issues, yet it often goes unrecognized and untreated.
- The study enrolled 420 patients aged 65+ with paroxysmal atrial fibrillation and moderate to severe OSA to compare the effects of Continuous Positive Airway Pressure (CPAP) treatment against no treatment over an average of 22 months.
- Results showed that CPAP significantly reduced the risk of major cardiovascular events (MACE) and recurrence of atrial fibrillation in patients when combined with regular medical care.
Article Abstract
Background: Obstructive sleep apnoea (OSA) is the most common and clinically significant sleep breathing disorder, with a high prevalence in elderly with cardiovascular diseases . OSA is often under-recognised and under-treated in clinical practice. The aim of this study is to investigate possible differences in major cardiovascular events (MACE) incidence and Paroxysmal Atrial Fibrillation (PAF) recurrence between patients receiving Continuous positive airway pressure (CPAP) treatment versus no CPAP treatment, in a cohort of elderly OSA patients with several comorbidities and history of PAF.
Methods: In this prospective observational study we enrolled 420 patients aged ≥65 years, suffering from PAF, with a first diagnosis of moderate/severe OSA and indication for CPAP-mode ventilotherapy. Patients underwent clinical-instrumental and laboratory evaluation for a mean follow-up of 22.0 months.
Results: CPAP treatment added on usual pharmacological care was associated with a reduced risk of MACE (HR 0.31, p < 0.001) and recurrence of PAF (HR 0.33, p < 0.001).
Conclusion: This study supports the role of moderate/severe OSA as a risk factor for MACE and recurrent AF. CPAP treatment with optimal compliance and good tolerability, combined with usual medical care for cardiometabolic comorbidities, is associated with a lower incidence of MACE and recurrent PAF in elderly with several comorbidities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejim.2024.12.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of continuous positive airway pressure therapy on early atherosclerosis in patients with severe obstructive sleep apnea-hypopnea syndrome.
Sleep Breath
January 2025
Faculty of Medicine, Department of Neurology, University of Debrecen, Moricz Zs. str. 22, Debrecen, H-4032, Hungary.
Purpose: Obstructive sleep apnea-hypopnea syndrome (OSAHS) is the most common sleep-related breathing disorder. Longer term, repeated episodes of hypercapnia and hypoxemia during sleep are associated with inflammatory and atherosclerosis-related factors. The aim of this study was to explore the effect of continuous positive airway pressure (CPAP) therapy on cerebral vasoreactivity and early atherosclerosis in patients with severe OSAHS.
View Article and Find Full Text PDFStudy of Demographic Characteristics, Management Details and Early Life Outcomes of Indigenous Infants With Chronic Neonatal Lung Disease in North Queensland.
J Paediatr Child Health
January 2025
Department of Paediatric Medicine, Townsville University Hospital, Townsville, Queensland, Australia.
Objective: To study the demographic characteristics, risk factors, management details and clinical outcomes to 12 months corrected age in indigenous and non-indigenous infants with chronic neonatal lung disease in North Queensland.
Design: Retrospective cohort study of infants with chronic neonatal lung disease admitted to a tertiary neonatal intensive care unit in regional Queensland from January 2015 to December 2019.
Results: There were 139 infants with chronic neonatal lung disease and 425 controls.
Cost effectiveness of obstructive sleep apnea therapies: a systematic review and meta-analysis of cost utility studies.
Expert Rev Pharmacoecon Outcomes Res
January 2025
Health Technology Assessment in India (HTAIn) Regional Resource Hub, ICMR-National Institute of Epidemiology, Chennai, India.
Objectives: Obstructive sleep apnea (OSA) is a sleep-related breathing disorder characterized by recurrent episodes of nocturnal breathing cessation resulting from upper airway collapse. Given the absence of a comprehensive review of the cost-effectiveness of OSA treatments, we undertook an extensive systematic review and meta-analysis to calculate the pooled incremental net benefit (INBp).
Methods: A systematic search of PubMed, Embase, Scopus, and Tufts cost-effectiveness analysis registry was conducted.
Challenges in Obstructive Sleep Apnea Management in Elderly Patients.
J Clin Med
December 2024
Department of Pulmonary Medicine, Saint-Pierre University Hospital, Brussels, Belgium and Université Libre de Bruxelles, 1000 Brussels, Belgium.
With the aging of the population, obstructive sleep apnea (OSA) in elderly patients is now more commonly seen in clinical practice. In older people, sleepiness is less marked than in younger patients, but insomnia symptoms are more common. Comorbidities are numerous and related to cardiometabolic and cognitive conditions.
View Article and Find Full Text PDFObjective Approach for Titration of Continuous Positive Airway Pressure in Patients with Obstructive Sleep Apnea Using Daytime Continuous Positive Airway Pressure Titration Based on Respiratory Movement Regularity.
J Clin Med
December 2024
Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.
: Continuous positive airway pressure (CPAP) is used to treat patients with obstructive sleep apnea (OSA) and has proven clinical efficacy for this condition. However, the objective method to determine the appropriate CPAP level for treatment is still unclear. Patients with OSA typically exhibit irregular respiratory efforts due to obstruction or narrowing of the upper airway during sleep.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!